flow trial semaglutide all-cause mortality hazard ratio SELECT Lower risk of cardiovascular events

While still investigational , the preliminary data are encouraging for those specializing in metabolic and cosmetic outcomes

Semaglutide mimics a hormone called GLP-1 thats usually released when the body detects carbohydrates, proteins, and other lipids after a meal

The cumulative effect translates to meaningful reductions in heart attack and stroke risk over time

Trends in Cardiovascular Medicine , 33 (3), 159166

That may include functional testing, trigger discovery, nutrition support, gut-focused care, selected supplements, detoxification support, and mitochondrial support when appropriate

So, clearly, the patients on the weight loss medication are going to achieve that outcome more easily